Previous 10 | Next 10 |
Available funding now exceeds remaining capex, with 84% of upfront expenditures committed (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 7, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides Q4 20...
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology PR Newswire GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost Pre-orders now open fo...
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting PR Newswire New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology ...
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 PR Newswire PLEASANTON, Calif. , Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced ...
2024-01-22 11:29:07 ET More on S&P 500 Index: S&P 500 Sets New Record High As Investors Potentially Shift Focus To Q2 2024 Market Rally Met With Outflows S&P 500: The 'Pump' Is Underway - Watch Out For The 'Dump' S&P won't get the helping hand...
2024-01-20 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings r...
2024-01-20 06:55:00 ET Summary 10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surp...
2024-01-20 02:20:35 ET Summary 10x Genomics specializes in medical devices and software for analyzing biodata, with impressive revenue growth but struggling to turn a profit. The company's products have been used in over 6,100 medical research publications and have helped create o...
2024-01-19 15:00:29 ET More on the markets SPY Is At Its Highest Risk Level (Technical Analysis) Recession Forecasting: Indicators That Actually Help Your Portfolio (Part 3) New Secular Bull Markets Hidden In Plain Sight Investors retract capital from the fun...
2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...
News, Short Squeeze, Breakout and More Instantly...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...